Press Room

ISPE UK Annual Conference 2023

Start
Thursday, November 30, 2023 - 15:45
Location: Coventry, United Kingdom

Join Hovione and GEA presentation at ISPE UK 2023

Title: “Delivering the Benefits of Continuous Tableting to the Pharmaceutical Industry”
 

Filipe Gaspar - VP Technology Intensification will be co-hosting a session at the event with Phillip Gabb from GEA focusing on the opportunities and challenges that Continuous Tableting presents to the pharmaceutical industry. In this session they will describe how both companies are working together and combining GEA´s engineering expertise with Hovione´s development and manufacturing experience to accelerate the adoption of this emerging technology.

 

This year's event, which will follow the established format of a full day of lectures, running alongside a bustling exhibition with over 45 manufacturers, suppliers and pharmaceutical industry decision makers during the day is followed by the ISPE Annual Awards Dinner in the evening. ISPE is a volunteer led organisation and the awards dinner is a chance to say 'thank you' to the volunteer members who enable events and training sessions throughout the year. 
 

Also in the Press Room

See All

The global inhalation contract development and manufacturing organization (CDMO) market is projected to grow from USD 9.13 billion in 2025 to USD 16.68 billion by 2035, reflecting a compound annual growth rate (CAGR) of 5.7% during the forecast period. This growth is driven by the increasing prevalence of respiratory diseases, advancements in inhalation drug delivery technologies, and the rising demand for outsourced manufacturing services in the pharmaceutical industry. The inhalation CDMO market has emerged as a pivotal segment in the pharmaceutical contract development and manufacturing industry. With a rising demand for inhaled therapies for conditions like asthma, COPD, and cystic fibrosis, companies are increasingly outsourcing drug development and production to specialized partners. Inhalation CDMO services cater to both large pharmaceutical corporations and small biotech firms, offering expertise in formulation, device compatibility, regulatory support, and scale-up manufacturing. This market is gaining traction due to the complexity of inhalation drug delivery, which often requires niche technical capabilities and specialized equipment. Outsourcing to an inhalation CDMO allows drug developers to reduce time-to-market while ensuring quality and compliance with global standards. (...) Top Companies Several players dominate the inhalation CDMO market through technological expertise, global reach, and service portfolio diversity: (...) Hovione – Offers particle engineering and inhalation development, with a focus on dry powder inhalers. (...) These companies are continually investing in facilities, talent, and technology to meet evolving customer needs in the inhalation CDMO market.   Read the full article on Pharmiweb.com        

Press Clipping

Inhalation CDMO Market Growth Analysis & Forecast 2025 to 2035

Jun 25, 2025